Current and emerging pharmacotherapy for chronic spontaneous Urticaria: a focus on non-biological therapeutics

References

• Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol. 1998;138(4):635–638.
   PubMed Web of Science ®Google Scholar
• Radonjic-Hoesli S, Hofmeier KS, Micaletto S, et al. Urticaria and angioedema: an update on classification and pathogenesis. Clin Rev Allergy Immunol. 2018;54(1):88–101.
   PubMed Web of Science ®Google Scholar
• Maurer M. Urticaria and angioedema. Chem Immunol Allergy.. 2014;100:101–104.
   PubMedGoogle Scholar
• Doong JC, Chichester K, Oliver ET, et al. Chronic idiopathic urticaria: systemic complaints and their relationship with disease and immune measures. J Allergy Clin Immunol Pract. 2017;5(5):1314–1318.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414.
   PubMed Web of Science ®Google Scholar
• Beck LA, Bernstein JA, Maurer MA. Review of international recommendations for the diagnosis and management of chronic Urticaria. Acta Derm Venereol. 2017;97(2):149–158.
   PubMed Web of Science ®Google Scholar
• Buss YA, Garrelfs UC, Sticherling M. Chronic urticaria–which clinical parameters are pathogenetically relevant? A retrospective investigation of 339 patients. J Dtsch Dermatol Ges. 2007;5(1):22–29.
   PubMedGoogle Scholar
• Lee XH, Ong LX, Cheong JY, et al. A stepwise approach in the management of chronic spontaneous urticaria in children. Asia Pac Allergy. 2016;6(1):16–28.
   PubMed Web of Science ®Google Scholar
• Schaefer P. Urticaria: evaluation and treatment. Am Fam Physician. 2011;83(9):1078–1084.
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Altrichter S, Munoz M, et al. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2020;124(1):2–12. DOI:10.1016/j.anai.2019.08.014.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Balke M, Worm M, et al. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol. 2010;35(8):869–873.
   PubMed Web of Science ®Google Scholar
• Ferrer M. Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Alergológica 2005. J Investig Allergol Clin Immunol. 2009;19(Suppl 2):21–26.
   PubMed Web of Science ®Google Scholar
• Greiwe J, Bernstein JA. Approach to the Patient with Hives. Med Clin North Am. 2020;104(1):15–24.
   PubMed Web of Science ®Google Scholar
• Parisi CA, Ritchie C, Petriz N, et al. Chronic urticaria in a health maintenance organization of Buenos Aires, Argentina - new data that increase global knowledge of this disease. An Bras Dermatol. 2018;93(1):76–79.
   PubMed Web of Science ®Google Scholar
• Lee N, Lee JD, Lee HY, et al. Epidemiology of chronic Urticaria in Korea using the Korean health insurance database, 2010–2014. Allergy Asthma Immunol Res. 2017;9(5):438–445.
   PubMed Web of Science ®Google Scholar
• Kim BR, Yang S, Choi JW, et al. Epidemiology and comorbidities of patients with chronic urticaria in Korea: A nationwide population-based study. J Dermatol. 2018;45(1):10–16.
   PubMed Web of Science ®Google Scholar
• Shin M, Lee S. Prevalence and Causes of Childhood Urticaria. Allergy Asthma Immunol Res. 2017;9(3):189–190.
   PubMed Web of Science ®Google Scholar
• Jain S. Pathogenesis of chronic urticaria: an overview. Dermatol Res Pract.. 2014;2014:674709.
   PubMedGoogle Scholar
• Guo C, Saltoun C. Urticaria and angioedema. Allergy Asthma Proc. 2019;40(6):437–440.
   PubMed Web of Science ®Google Scholar
• Bracken SJ, Abraham S, MacLeod AS. Autoimmune theories of chronic spontaneous Urticaria. Front Immunol. 2019;10:627.
   PubMed Web of Science ®Google Scholar
• Church MK, Kolkhir P, Metz M, et al. The role and relevance of mast cells in urticaria. Immunol Rev. 2018;282(1):232–247.
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017;139(6):1772–1781.e1.
   PubMed Web of Science ®Google Scholar
• Kasumagic-Halilovic E, Beslic N, Ovcina-Kurtovic N. Thyroid autoimmunity in patients with chronic Urticaria. Med Arch. 2017;71(1):29–31.
   PubMedGoogle Scholar
• Netchiporouk E, Sasseville D, Moreau L, et al. Evaluating comorbidities, natural history, and predictors of early resolution in a cohort of children with chronic Urticaria. JAMA Dermatol. 2017;153(12):1236–1242.
   PubMed Web of Science ®Google Scholar
• Awosika O, Qureshi A, Ehrlich A, et al. “Chronic Urticaria”: recommendations from an allergist and immunologist. Dermatitis. 2018;29(5):292–293.
   PubMed Web of Science ®Google Scholar
• Hermes B, Prochazka AK, Haas N, et al. Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol. 1999;103(2 Pt 1):307–314.
   PubMed Web of Science ®Google Scholar
• Lourenço FD, Azor MH, Santos JC, et al. Activated status of basophils in chronic urticaria leads to interleukin-3 hyper-responsiveness and enhancement of histamine release induced by anti-IgE stimulus. Br J Dermatol. 2008;158(5):979–986. DOI:10.1111/j.1365-2133.2008.08499.x.
   PubMed Web of Science ®Google Scholar
• Kudryavtseva AV, Neskorodova KA, Staubach P. Urticaria in children and adolescents: an updated review of the pathogenesis and management. Pediatr Allergy Immunol. 2019;30(1):17–24.
   PubMed Web of Science ®Google Scholar
• Deacock SJ. An approach to the patient with urticaria. Clin Exp Immunol. 2008;153(2):151–161.
   PubMed Web of Science ®Google Scholar
• Hives (Urticaria) . ACAAI Public Website. 2014 [cited 2020 Mar 11]. Available from: https://acaai.org/allergies/types-allergies/hives-urticaria
   Google Scholar
• Leung AKC. Urticaria. In: Lang F, editor. The encyclopedia of molecular mechanisms of disease. Berlin: Springer-Verlag; 2009. p. 2153–2154.
   Google Scholar
• Kulthanan K, Tuchinda P, Chularojanamontri L, et al. Clinical practice guideline for diagnosis and management of urticaria. Asian Pac J Allergy Immunol. 2016;34(3):190–200.
   PubMed Web of Science ®Google Scholar
• Saini SS, Kaplan AP. Chronic spontaneous Urticaria: the Devil’s Itch. J Allergy Clin Immunol Pract. 2018;6(4):1097–1106.
   PubMed Web of Science ®Google Scholar
• Leung AK, Robson WL. Penile and oral angioedema associated with peanut ingestion. J Natl Med Assoc. 2006;98(12):2011–2012.
   PubMed Web of Science ®Google Scholar
• Kocatürk E, Maurer M, Metz M, et al. Looking forward to new targeted treatments for chronic spontaneous urticaria [published correction appears in Clin Transl Allergy. 2017 Apr 3;7:11]. Clin Transl Allergy.. 2017;7:(1):1. DOI:10.1186/s13601-016-0139-2
   PubMedGoogle Scholar
• Kolkhir P, Altrichter S, Hawro T, et al. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy. 2018;73(4):940–948.
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Pogorelov D, Olisova O. CRP, D-dimer, fibrinogen and ESR as predictive markers of response to standard doses of levocetirizine in patients with chronic spontaneous urticaria. Eur Ann Allergy Clin Immunol. 2017;49(4):189–192.
   PubMed Web of Science ®Google Scholar
• Hon KL, Leung AKC, Ng WGG, et al. Chronic Urticaria: an overview of treatment and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2019;13(1):27–37.
   PubMed Web of Science ®Google Scholar
• Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr. 2019;45(1):101.
   PubMed Web of Science ®Google Scholar
• Poornimambaa M, Asokan N, Augustine J. Utility of direct immunofluorescence in the diagnosis of small vessel vasculitis of the skin: a cross-sectional study. Indian Dermatol Online J. 2017;8(6):515–517.
   PubMedGoogle Scholar
• Kolkhir P, Pogorelov D, Darlenski R, et al. Management of chronic spontaneous urticaria: a worldwide perspective. World Allergy Organ J. 2018;11(1):14.
   PubMedGoogle Scholar
• Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270–1277. DOI:10.1016/j.jaci.2014.02.036.
   PubMed Web of Science ®Google Scholar
• Fine LM, Bernstein JA. Urticaria guidelines: consensus and controversies in the European and American guidelines. Curr Allergy Asthma Rep. 2015;15(6):30.
   PubMed Web of Science ®Google Scholar
• Schaefer P. Acute and chronic Urticaria: evaluation and treatment. Am Fam Physician. 2017;95(11):717–724.
   PubMed Web of Science ®Google Scholar
• Antia C, Baquerizo K, Korman A, et al. Urticaria: a comprehensive review: treatment of chronic urticaria, special populations, and disease outcomes. J Am Acad Dermatol. 2018;79(4):617–633.
   PubMed Web of Science ®Google Scholar
• Zuberbier T. A summary of the new international EAACI/GA2LEN/EDF/WAO guidelines in Urticaria. World Allergy Organ J. 2012;5(Suppl 1):S1–S5.
   PubMedGoogle Scholar
• Sharma M, Bennett C, Cohen SN, et al. H1-antihistamines for chronic spontaneous urticaria. Cochrane Database Syst Rev. 2014;2014(11):CD006137.
   Google Scholar
• Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45(3):547–565. DOI:10.1111/cea.12494.
   PubMed Web of Science ®Google Scholar
• Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria [published correction appears in N Engl J Med. 2013 Jun 13;368(24):2340–1]. N Engl J Med. 2013;368(10):924–935. DOI:10.1056/NEJMoa1215372.
   PubMed Web of Science ®Google Scholar
• Cordeiro Moreira AS, Rosmaninho Lopes de Soares E Silva MI, Pereira Guilherme MA, et al. Use of omalizumab in the treatment of chronic urticaria. Eur Ann Allergy Clin Immunol. 2016;48(6):242–246.
   PubMed Web of Science ®Google Scholar
• Holgate ST, Djukanović R, Casale T, et al. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy. 2005;35(4):408–416.
   PubMed Web of Science ®Google Scholar
• Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005–2016.
   PubMed Web of Science ®Google Scholar
• Criado PR, Criado RF, Maruta CW, et al. Chronic urticaria in adults: state-of-the-art in the new millennium. An Bras Dermatol. 2015;90(1):74–89.
   PubMed Web of Science ®Google Scholar
• Labrador-Horrillo M, Ferrer M. Profile of omalizumab in the treatment of chronic spontaneous urticaria. Drug Des Devel Ther. 2015;9:4909–4915.
   PubMed Web of Science ®Google Scholar
• Grattan CE, O’Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol. 2000;143(2):365–372.
   PubMed Web of Science ®Google Scholar
• Vena GA, Cassano N, Colombo D, et al. Neo-I-30 Study Group. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2006;55(4):705–709.
   PubMed Web of Science ®Google Scholar
• Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for chronic spontaneous Urticaria: a meta-analysis and systematic review. J Allergy Clin Immunol Pract. 2018;6(2):586–599.
   PubMed Web of Science ®Google Scholar
• Doshi DR, Weinberger MM. Experience with cyclosporine in children with chronic idiopathic urticaria. Pediatr Dermatol. 2009;26(4):409–413.
   PubMed Web of Science ®Google Scholar
• Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol. 2010;20(5):386–390.
   PubMed Web of Science ®Google Scholar
• Maurer M, Magerl M, Metz M, et al. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. J Dtsch Dermatol Ges. 2013;11(10):971–978.
   PubMed Web of Science ®Google Scholar
• Asero R. Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma Immunol. 2000;85(2):156–157.
   PubMed Web of Science ®Google Scholar
• de Silva NL, Damayanthi H, Rajapakse AC, et al. Leukotriene receptor antagonists for chronic urticaria: a systematic review. Allergy Asthma Clin Immunol. 2014;10(1):24.
   PubMedGoogle Scholar
• Cugno M, Marzano AV, Asero R, et al. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. Intern Emerg Med. 2010;5(2):97–101.
   PubMed Web of Science ®Google Scholar
• Cugno M, Borghi A, Garcovich S, et al. Coagulation and skin autoimmunity. Front Immunol. 2019;10:1407.
   PubMed Web of Science ®Google Scholar
• Fujii K, Usuki A, Kan-No Y, et al. Elevation of circulating thrombin-antithrombin III complex and fibrin degradation products in urticaria: a laboratory finding unrelated to intravascular coagulopathy. J Dermatol. 2008;35(5):308–310.
   PubMed Web of Science ®Google Scholar
• Cugno M, Tedeschi A, Borghi A, et al. Activation of blood coagulation in two prototypic autoimmune skin diseases: a possible link with thrombotic risk. PLoS One. 2015;10(6):e0129456.
   PubMed Web of Science ®Google Scholar
• Wang F, Tang H, Xu JH, et al. Activation of the blood coagulation cascade is involved in patients with chronic urticaria. J Allergy Clin Immunol. 2009;123(4):972–974.
   PubMed Web of Science ®Google Scholar
• Grzanka R, Damasiewicz-Bodzek A, Kasperska-Zajac A. Interplay between acute phase response and coagulation/fibrinolysis in chronic spontaneous urticaria. Allergy Asthma Clin Immunol.. 2018;14:27.
   PubMed Web of Science ®Google Scholar
• Asero R, Tedeschi A, Riboldi P, et al. Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy. 2008;63(2):176–180.
   PubMed Web of Science ®Google Scholar
• Chua SL, Gibbs S. Chronic urticaria responding to subcutaneous heparin sodium. Br J Dermatol. 2005;153(1):216–217.
   PubMed Web of Science ®Google Scholar
• Spring P, Angelillo-Scherrer A, Bigliardi P. Chronic idiopathic urticaria successfully treated by anticoagulant drugs. Eur J Dermatol. 2012;22(6):788–790.
   PubMed Web of Science ®Google Scholar
• Asero R, Tedeschi A, Cugno M. Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int Arch Allergy Immunol. 2010;152(4):384–389.
   PubMed Web of Science ®Google Scholar
• Asero R, Tedeschi A, Marzano A, et al. Coagulation in chronic Urticaria. Curr Treat Options Allergy. 2015;2(4):287–293.
   Google Scholar
• Tant D. Tranexamic acid in chronic urticaria. Br Med J. 1979;1(6158):266.
   PubMedGoogle Scholar
• Laurberg G. Tranexamic acid (Cyklokapron) in chronic urticaria: a double-blind study. Acta Derm Venereol. 1977;57(4):369–370.
   PubMed Web of Science ®Google Scholar
• Takahagi S, Shindo H, Watanabe M, et al. Refractory chronic urticaria treated effectively with the protease inhibitors, nafamostat mesilate and camostat mesilate. Acta Derm Venereol. 2010;90(4):425–426.
   PubMed Web of Science ®Google Scholar
• Eskeland S, Halvorsen JA, Tanum L. Antidepressants have anti-inflammatory effects that may be relevant to dermatology: a systematic review. Acta Derm Venereol. 2017;97(8):897–905.
   PubMed Web of Science ®Google Scholar
• Baharav E, Bar M, Taler M, et al. Immunomodulatory effect of sertraline in a rat model of rheumatoid arthritis. Neuroimmunomodulation. 2012;19(5):309–318.
   PubMed Web of Science ®Google Scholar
• Ghia JE, Blennerhassett P, Deng Y, et al. Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology. 2009;136(7):2280–2288.e22884.
   PubMed Web of Science ®Google Scholar
• Brown ES, Howard C, Khan DA, et al. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study. Psychosomatics. 2012;53(1):75–80.
   PubMed Web of Science ®Google Scholar
• Iskandar HN, Cassell B, Kanuri N, et al. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol. 2014;48(5):423–429.
   PubMed Web of Science ®Google Scholar
• Greene SL, Reed CE, Schroeter AL. Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. J Am Acad Dermatol. 1985;12(4):669–675.
   PubMed Web of Science ®Google Scholar
• Tilles SA. Approach to therapy in chronic urticaria: when benadryl is not enough. Allergy Asthma Proc. 2005;26(1):9–12.
   PubMed Web of Science ®Google Scholar
• Bigatà X, Sais G, Soler F. Severe chronic urticaria: response to mirtazapine. J Am Acad Dermatol. 2005;53(5):916–917.
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK. Chronic idiopathic urticaria associated with panic disorder: a syndrome responsive to selective serotonin reuptake inhibitor antidepressants? Cutis. 1995;56(1):53–54.
   PubMed Web of Science ®Google Scholar
• Bonney RJ, Wightman PD, Dahlgren ME, et al. Inhibition of the release of prostaglandins, leukotrienes and lysosomal acid hydrolases from macrophages by selective inhibitors of lecithin biosynthesis. Biochem Pharmacol. 1983;32(2):361–366.
   PubMed Web of Science ®Google Scholar
• Bozeman PM, Learn DB, Thomas EL. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem Pharmacol. 1992;44(3):553–563.
   PubMed Web of Science ®Google Scholar
• Booth SA, Moody CE, Dahl MV, et al. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol. 1992;98(2):135–140.
   PubMed Web of Science ®Google Scholar
• Debol SM, Herron MJ, Nelson RD. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol. 1997;62(6):827–836.
   PubMed Web of Science ®Google Scholar
• Theron A, Anderson R. Investigation of the protective effects of the antioxidants ascorbate, cysteine, and dapsone on the phagocyte-mediated oxidative inactivation of human alpha-1-protease inhibitor in vitro. Am Rev Respir Dis. 1985;132(5):1049–1054.
   PubMedGoogle Scholar
• Morgan M, Cooke A, Rogers L, et al. Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria [published correction appears in J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):823]. J Allergy Clin Immunol Pract. 2014;2(5):601–606.
   PubMed Web of Science ®Google Scholar
• Liang SE, Hoffmann R, Peterson E, et al. Use of dapsone in the treatment of chronic idiopathic and autoimmune Urticaria. JAMA Dermatol. 2019;155(1):90–95.
   PubMed Web of Science ®Google Scholar
• Gadangi P, Longaker M, Naime D, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996;156(5):1937–1941.
   PubMed Web of Science ®Google Scholar
• Fox CC, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1991;36(2):179–184.
   PubMed Web of Science ®Google Scholar
• Suematsu M, Suzuki M, Miura S, et al. Sulfasalazine and its metabolites attenuate respiratory burst of leukocytes–a possible mechanism of anti-inflammatory effects. J Clin Lab Immunol. 1987;23(1):31–33.
   PubMedGoogle Scholar
• Imai F, Suzuki T, Ishibashi T, et al. Effect of sulfasalazine on B cells. Clin Exp Rheumatol. 1991;9(3):259–264.
   PubMed Web of Science ®Google Scholar
• Orden RA, Timble H, Saini SS. Efficacy and safety of sulfasalazine in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2014;112(1):64–70.
   PubMed Web of Science ®Google Scholar
• Cream JJ, Pole DS. The effect of methotrexate and hydroxyurea on neutrophil chemotaxis. Br J Dermatol. 1980;102(5):557–563.
   PubMed Web of Science ®Google Scholar
• Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002;4(4):266–273.
   PubMedGoogle Scholar
• Sperling RI, Coblyn JS, Larkin JK, et al. Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis Rheum. 1990;33(8):1149–1155.
   PubMedGoogle Scholar
• Gerards AH, de Lathouder S, de Groot ER, et al. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford). 2003;42(10):1189–1196.
   PubMed Web of Science ®Google Scholar
• Perez A, Woods A, Grattan CE. Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol. 2010;162(1):191–194.
   PubMed Web of Science ®Google Scholar
• Sagi L, Solomon M, Baum S, et al. Evidence for methotrexate as a useful treatment for steroid-dependent chronic urticaria. Acta Derm Venereol. 2011;91(3):303–306.
   PubMed Web of Science ®Google Scholar
• Leducq S, Samimi M, Bernier C, et al. Efficacy and safety of methotrexate versus placebo as add-on therapy to H1 antihistamines for patients with difficult-to-treat chronic spontaneous urticaria: A randomized, controlled trial. J Am Acad Dermatol. 2020;82(1):240–243. DOI:10.1016/j.jaad.2019.07.097.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Singh S, Ramam M, et al. A randomized placebo-controlled double-blind pilot study of methotrexate in the treatment of H1 antihistamine-resistant chronic spontaneous urticaria. Indian J Dermatol Venereol Leprol. 2014;80(2):122–128.
   PubMed Web of Science ®Google Scholar
• Sandhu MS, Casale TB. The role of vitamin D in asthma. Ann Allergy Asthma Immunol. 2010;105(3):191–217.
   PubMed Web of Science ®Google Scholar
• Bozzetto S, Carraro S, Giordano G, et al. Asthma, allergy and respiratory infections: the vitamin D hypothesis. Allergy. 2012;67(1):10–17.
   PubMed Web of Science ®Google Scholar
• Jones AP, Tulic MK, Rueter K, et al. Vitamin D and allergic disease: sunlight at the end of the tunnel? Nutrients. 2012;4(1):13–28.
   PubMed Web of Science ®Google Scholar
• Rather S, Keen A, Sajad P. Serum Levels of 25-hydroxyvitamin D in Chronic Urticaria and its Association with Disease Activity: A Case Control Study. Indian Dermatol Online J. 2018;9(3):170–174.
   PubMedGoogle Scholar
• Tuchinda P, Kulthanan K, Chularojanamontri L, et al. Relationship between vitamin D and chronic spontaneous urticaria: a systematic review. Clin Transl Allergy.. 2018;8(1):51. DOI:10.1186/s13601-018-0234-7
   PubMedGoogle Scholar
• Abdel-Rehim AS, Sheha DS, Mohamed NA. Vitamin D level among Egyptian patients with chronic spontaneous urticaria and its relation to severity of the disease. Egypt J Immunol. 2014;21(2):85–90.
   PubMedGoogle Scholar
• Chandrashekar L, Rajappa M, Munisamy M, et al. 25-Hydroxy vitamin D levels in chronic urticaria and its correlation with disease severity from a tertiary care centre in South India. Clin Chem Lab Med. 2014;52(6):e115–e118.
   PubMed Web of Science ®Google Scholar
• Tsai TY, Huang YC. Vitamin D deficiency in patients with chronic and acute urticaria: A systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(3):573–575.
   PubMed Web of Science ®Google Scholar
• Heaney RP. Vitamin D–baseline status and effective dose. N Engl J Med. 2012;367(1):77–78.
   PubMed Web of Science ®Google Scholar
• Stokes CS, Lammert F. Vitamin D supplementation: less controversy, more guidance needed. F1000Res. 2016;5 :F1000 Faculty Rev–2017.
   PubMedGoogle Scholar
• Pathania YS, Bishnoi A, Parsad D, et al. Comparing azathioprine with cyclosporine in the treatment of antihistamine refractory chronic spontaneous urticaria: A randomized prospective active-controlled non-inferiority study. World Allergy Organ J. 2019;12(5):100033.
   PubMed Web of Science ®Google Scholar
• Tal Y, Toker O, Agmon-Levin N, et al. Azathioprine as a therapeutic alternative for refractory chronic urticaria. Int J Dermatol. 2015;54(3):367–369.
   PubMed Web of Science ®Google Scholar
• Bhanja DC, Ghoshal L, Das S, et al. Azathioprine in autologous serum skin test positive chronic urticaria: a case-control study in a tertiary care hospital of eastern India. Indian Dermatol Online J. 2015;6(3):185–188.
   PubMedGoogle Scholar
• Reeves GE, Boyle MJ, Bonfield J, et al. Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J. 2004;34(4):182–186.
   PubMed Web of Science ®Google Scholar
• Pho LN, Eliason MJ, Regruto M, et al. Treatment of chronic urticaria with colchicine. J Drugs Dermatol. 2011;10(12):1423–1428.
   PubMed Web of Science ®Google Scholar
• Criado RF, Criado PR, Martins JE, et al. Urticaria unresponsive to antihistaminic treatment: an open study of therapeutic options based on histopathologic features. J Dermatolog Treat. 2008;19(2):92–96.
   PubMed Web of Science ®Google Scholar
• Asero R. Oral cyclophosphamide in a case of cyclosporin and steroid-resistant chronic urticaria showing autoreactivity on autologous serum skin testing. Clin Exp Dermatol. 2005;30(5):582–583.
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Garramone SM, Lower EG. Successful treatment of autoimmune chronic idiopathic urticaria with intravenous cyclophosphamide. Ann Allergy Asthma Immunol. 2002;89(2):212–214.
   PubMed Web of Science ®Google Scholar
• Raghavendran RR, Humphreys F, Kaur MR. Successful use of mycophenolate mofetil to treat severe chronic urticaria in a patient intolerant to ciclosporin. Clin Exp Dermatol. 2014;39(1):68–69.
   PubMed Web of Science ®Google Scholar
• Shahar E, Bergman R, Guttman-Yassky E, et al. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol. 2006;45(10):1224–1227.
   PubMed Web of Science ®Google Scholar
• Zimmerman AB, Berger EM, Elmariah SB, et al. The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients. J Am Acad Dermatol. 2012;66(5):767–770.
   PubMed Web of Science ®Google Scholar
• McAdoo S, Tam FWK. Role of the spleen tyrosine kinase pathway in driving inflammation in IgA nephropathy. Semin Nephrol. 2018;38(5):496–503.
   PubMed Web of Science ®Google Scholar
• Kulathu Y, Grothe G, Reth M. Autoinhibition and adapter function of Syk. Immunol Rev. 2009;232(1):286–299.
   PubMedGoogle Scholar
• Turner M, Schweighoffer E, Colucci F, et al. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today. 2000;21(3):148–154.
   PubMedGoogle Scholar
• Ma TK, McAdoo SP, Tam FW. Spleen tyrosine kinase: a crucial player and potential therapeutic target in renal disease. Nephron. 2016;133(4):261–269.
   PubMed Web of Science ®Google Scholar
• Kikuchi Y, Kaplan AP. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol. 2001;107(6):1056–1062.
   PubMed Web of Science ®Google Scholar
• Ramirez Molina C, Falkencrone S, Skov PS, et al. GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin. Br J Pharmacol. 2019;176(8):1135–1142. DOI:10.1111/bph.14610.
   PubMed Web of Science ®Google Scholar
• Min TK, Saini SS. Emerging Therapies in Chronic Spontaneous Urticaria. Allergy Asthma Immunol Res. 2019;11(4):470–481.
   PubMed Web of Science ®Google Scholar
• Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies [published correction appears in Mol Cancer. 2019 Apr 3;18(1):79]. Mol Cancer. 2018;17(1):57.
   PubMedGoogle Scholar
• Ponader S, Burger JA. Bruton’s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol. 2014;32(17):1830–1839.
   PubMed Web of Science ®Google Scholar
• Dispenza MC, Pongracic JA, Singh AM, et al. Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy [published correction appears in J Allergy Clin Immunol. 2018 Oct;142(4):1374]. J Allergy Clin Immunol. 2018;141(5):1914–1916.e7.
   PubMed Web of Science ®Google Scholar
• Johal KJ, Saini SS. Current and emerging treatments for chronic spontaneous urticaria [published online ahead of print, 2019 Sep 5]. Ann Allergy Asthma Immunol. 2020;125(4):380-387.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov A study to evaluate the long-term safety and efficacy of fenebrutinib in participants previously enrolled in a fenebrutinib chronic spontaneous Urticaria (CSU) study. 2020 [cited 2020 Mar 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT03693625
   Google Scholar
• ClinicalTrials.gov Efficacy and safety of GDC-0853 in participants with refractory chronic spontaneous Urticaria (CSU). 2020 [cited 2020 Mar 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT03137069
   Google Scholar
• Kaul M, Storim J, End P, et al. LOU064: A highly selective and potent covalent oral BTK inhibitor with promising pharmacodynamic effects in skin. Allergy. 2019;74(S106):333–376. (Abstract LBPD1718).
   PubMedGoogle Scholar
• Angst D, Gessier F, Janser P, et al. Discovery of LOU064 (Remibrutinib), a potent and highly selective covalent inhibitor of Bruton’s Tyrosine Kinase. J Med Chem. 2020;63(10):5102–5118. DOI:10.1021/acs.jmedchem.9b01916.
   PubMed Web of Science ®Google Scholar
• Gabizon R, London N. A fast and clean BTK inhibitor. J Med Chem. 2020;63(10):5100–5101.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov Dose-finding study to evaluate efficacy and safety of LOU064 in patients with CSU inadequately controlled by H1-antihistamines. 2020 [cited 2020 Jul 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT03926611
   Google Scholar
• Ying S, Kikuchi Y, Meng Q, et al. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol. 2002;109(4):694–700.
   PubMed Web of Science ®Google Scholar
• Gervais FG, Cruz RP, Chateauneuf A, et al. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP. J Allergy Clin Immunol. 2001;108(6):982–988. DOI:10.1067/mai.2001.119919.
   PubMed Web of Science ®Google Scholar
• Kupczyk M, Kuna P. Targeting the PGD2/CRTH2/DP1 signaling pathway in asthma and allergic disease: current status and future perspectives. Drugs. 2017;77(12):1281–1294.
   PubMed Web of Science ®Google Scholar
• Townley RG, Agrawal S. CRTH2 antagonists in the treatment of allergic responses involving TH2 cells, basophils, and eosinophils. Ann Allergy Asthma Immunol. 2012;109(6):365–374.
   PubMed Web of Science ®Google Scholar
• Oliver ET, Chichester K, Devine K, et al. Effects of an oral CRTh2 antagonist (AZD1981) on eosinophil activity and symptoms in chronic spontaneous urticaria [published correction appears in int arch allergy immunol. 2019;179(4):320]. Int Arch Allergy Immunol. 2019;179(1):21–30. DOI:10.1159/000496162.
   PubMed Web of Science ®Google Scholar
• Soter NA, Lewis RA, Corey EJ, et al. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol. 1983;80(2):115–119.
   PubMed Web of Science ®Google Scholar
• Oliver ET, Sterba PM, Devine K, et al. Altered expression of chemoattractant receptor-homologous molecule expressed on T(H)2 cells on blood basophils and eosinophils in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2016;137(1):304–306.e1.
   PubMed Web of Science ®Google Scholar
• Thurmond RL. The histamine H4 receptor: from orphan to the clinic. Front Pharmacol. 2015;6:65.
   PubMed Web of Science ®Google Scholar
• Thurmond RL, Desai PJ, Dunford PJ, et al. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther. 2004;309(1):404–413. DOI:10.1124/jpet.103.061754.
   PubMed Web of Science ®Google Scholar
• Tatarkiewicz J, Rzodkiewicz P, Żochowska M, et al. New antihistamines - perspectives in the treatment of some allergic and inflammatory disorders. Arch Med Sci. 2019;15(2):537–553.
   PubMed Web of Science ®Google Scholar
• Thurmond RL, Chen B, Dunford PJ, et al. Clinical and preclinical characterization of the histamine H(4) receptor antagonist JNJ-39758979. J Pharmacol Exp Ther. 2014;349(2):176–184. DOI:10.1124/jpet.113.211714.
   PubMed Web of Science ®Google Scholar
• Savall BM, Chavez F, Tays K, et al. Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H₄ receptor antagonists. J Med Chem. 2014;57(6):2429–2439. DOI:10.1021/jm401727m.
   PubMed Web of Science ®Google Scholar
• Kollmeier A, Francke K, Chen B, et al. The histamine H₄ receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects. J Pharmacol Exp Ther. 2014;350(1):181–187. DOI:10.1124/jpet.114.215749.
   PubMed Web of Science ®Google Scholar
• Bader M, Alenina N, Andrade-Navarro MA, et al. S and its related G protein-coupled receptors, Mrgprs. Pharmacol Rev. 2014;66(4):1080–1105.
   PubMed Web of Science ®Google Scholar
• Ali H. Emerging roles for MAS-related G protein-coupled receptor-X2 in host defense peptide, opioid, and neuropeptide-mediated inflammatory reactions. Adv Immunol.. 2017;136:123–162.
   PubMed Web of Science ®Google Scholar
• Fujisawa D, Kashiwakura J, Kita H, et al. Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. J Allergy Clin Immunol. 2014;134(3):622–633.e9.
   PubMed Web of Science ®Google Scholar
• Subramanian H, Gupta K, Ali H. Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases. J Allergy Clin Immunol. 2016;138(3):700–710.
   PubMed Web of Science ®Google Scholar
• Vena GA, Cassano N, Di Leo E, et al. Focus on the role of substance P in chronic urticaria. Clin Mol Allergy.. 2018;16(1):24. DOI:10.1186/s12948-018-0101-z
   PubMedGoogle Scholar
• Porebski G, Kwiecien K, Pawica M, et al. Mas-related G protein-coupled receptor-X2 (MRGPRX2) in drug hypersensitivity reactions. Front Immunol. 2018;9:3027.
   PubMed Web of Science ®Google Scholar
• Zhang ZR, Leung WN, Cheung HY, et al. Osthole: a review on its bioactivities, pharmacological properties, and potential as alternative medicine. Evid Based Complement Alternat Med. 2015;2015:919616.
   PubMed Web of Science ®Google Scholar
• Callahan BN, Kammala AK, Syed M, et al. Osthole, a natural plant derivative inhibits MRGPRX2 induced mast cell responses. Front Immunol. 2020;11:703.
   PubMed Web of Science ®Google Scholar
• Ogasawara H, Furuno M, Edamura K, et al. Novel MRGPRX2 antagonists inhibit IgE-independent activation of human umbilical cord blood-derived mast cells. J Leukoc Biol. 2019;106(5):1069–1077.
   PubMed Web of Science ®Google Scholar
• Roy S, Ganguly A, Haque M, et al. Angiogenic host defense peptide AG-30/5C and bradykinin B2 receptor antagonist icatibant are G protein biased agonists for MRGPRX2 in mast cells. J Immunol. 2019;202(4):1229–1238.
   PubMed Web of Science ®Google Scholar
• NCI Dictionary of Cancer Terms . National cancer institute. 2020 [cited 2020 Jul 22]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biological-therapy
   Google Scholar
• Bulkhi A, Cooke AJ, Casale TB. Biologics in chronic Urticaria. Immunol Allergy Clin North Am. 2017;37(1):95–112.
   PubMed Web of Science ®Google Scholar
• Kocatürk E, Zuberbier T. New biologics in the treatment of urticaria. Curr Opin Allergy Clin Immunol. 2018;18(5):425–431.
   PubMed Web of Science ®Google Scholar
• Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11(1):165. DOI:10.1038/s41467-019-13815-w.
   PubMed Web of Science ®Google Scholar
• Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014;44(11):1371–1385. DOI:10.1111/cea.12400.
   PubMed Web of Science ®Google Scholar
• Maurer M, Giménez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous Urticaria. N Engl J Med. 2019;381(14):1321–1332. DOI:10.1056/NEJMoa1900408.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines. 2020 [cited 2020 Jul 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT03580369
   Google Scholar
• Marques RZ, Criado RF, Filho MCD, et al. Correlation between the histopathology of chronic urticaria and its clinical picture. An Bras Dermatol. 2016;91(6):760–763.
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Church MK, Altrichter S, et al. Eosinopenia, in chronic spontaneous Urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment. J Allergy Clin Immunol Pract. 2020;8(1):318–325.e5. DOI:10.1016/j.jaip.2019.08.025.
   PubMed Web of Science ®Google Scholar
• Altrichter S, Frischbutter S, Fok JS, et al. The role of eosinophils in chronic spontaneous urticaria. J Allergy Clin Immunol. 2020;145(6):1510–1516. DOI:10.1016/j.jaci.2020.03.005.
   PubMed Web of Science ®Google Scholar
• Roufosse F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med (Lausanne). 2018;5:49.
   PubMed Web of Science ®Google Scholar
• Cosmi L, Maggi L, Mazzoni A, et al. Biologicals targeting type 2 immunity: lessons learned from asthma, chronic urticaria and atopic dermatitis. Eur J Immunol. 2019;49(9):1334–1343.
   PubMed Web of Science ®Google Scholar
• Maurer M, Altrichter S, Metz M, et al. Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. J Eur Acad Dermatol Venereol. 2018;32(3):e112–e113.
   PubMed Web of Science ®Google Scholar
• Bergmann KC, Altrichter S, Maurer M. Benefit of benralizumab treatment in a patient with chronic symptomatic dermographism. J Eur Acad Dermatol Venereol. 2019;33(11):e413–e415.
   PubMed Web of Science ®Google Scholar
• Caproni M, Cardinali C, Giomi B, et al. Serological detection of eotaxin, IL-4, IL-13, IFN-gamma, MIP-1alpha, TARC and IP-10 in chronic autoimmune urticaria and chronic idiopathic urticaria. J Dermatol Sci. 2004;36(1):57–59. DOI:10.1016/j.jdermsci.2004.07.006.
   PubMed Web of Science ®Google Scholar
• Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–1204. DOI:10.1111/all.14151.
   PubMed Web of Science ®Google Scholar
• Kariyawasam HH, James LK, Gane SB. Dupilumab: clinical efficacy of blocking IL-4/IL-13 signalling in chronic rhinosinusitis with nasal polyps. Drug Des Devel Ther. 2020;14:1757–1769.
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Ferrando M, Varricchi G, et al. A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma. Int Arch Allergy Immunol. 2016;170(2):122–131.
   PubMed Web of Science ®Google Scholar
• Dupixent (dupilumab) [package insert]. U.S. food and drug administration. 2020
   Google Scholar
• ClinicalTrials.gov Dupilumab for the treatment of chronic spontaneous urticaria in patients who remain symptomatic despite the use of H1 antihistamine and who are naïve to, intolerant of, or incomplete responders to omalizumab (CUPID). 2020 [cited 2020 Jul 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04180488 https://clinicaltrials.gov/ct2/show/NCT03926611
   Google Scholar
• Sand FL, Thomsen SF. Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients. Dermatol Ther. 2015;28(3):158–165.
   PubMed Web of Science ®Google Scholar
• Sand FL, Thomsen SF. TNF-alpha inhibitors for chronic urticaria: experience in 20 patients. J Allergy (Cairo).. 2013;2013:130905.
   PubMedGoogle Scholar
• Combalia A, Losno RA, Prieto-González S, et al. Rituximab in refractory chronic spontaneous urticaria: an encouraging therapeutic approach. Skin Pharmacol Physiol. 2018;31(4):184–187.
   PubMed Web of Science ®Google Scholar
• Machura E, Szczepańska M, Mazur B, et al. Interleukin 1-β, interleukin-1 receptor antagonist, and interleukin 18 in children with acute spontaneous urticaria. Biomed Res Int. 2013;2013:605262.
   PubMed Web of Science ®Google Scholar
• Lenormand C, Lipsker D. Efficiency of interleukin-1 blockade in refractory delayed-pressure urticaria. Ann Intern Med. 2012;157(8):599–600.
   PubMed Web of Science ®Google Scholar
• Lavinka PC, Dong X. Molecular signaling and targets from itch: lessons for cough. Cough. 2013;9(1):8.
   PubMedGoogle Scholar
• Rinaldi G. The itch-scratch cycle: a review of the mechanisms. Dermatol Pract Concept. 2019;9(2):90–97.
   PubMedGoogle Scholar
• Vestergaard C, Toubi E, Maurer M, et al. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion. Eur J Dermatol. 2017;27(1):10–19. DOI:10.1684/ejd.2016.2905.
   PubMed Web of Science ®Google Scholar